NKTR 358

Drug Profile

NKTR 358

Alternative Names: NKTR-358

Latest Information Update: 26 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nektar Therapeutics
  • Class
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 24 Jul 2017 Nektar Therapeutics and Eli Lilly agree to co-develop NKTR 358 for Autoimmune disorders worldwide
  • 10 Jul 2017 Interim preclinical study results in Autoimmune disorders released by Nectar Therapeutics
  • 29 Mar 2017 Pharmacodynamics data from preclinical studies in Autoimmune disorders released by Nektar Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top